Regeneron founder, chair and CEO Leonard Schleifer joins 'Squawk Box' to discuss the impact of President Trump's tariff policies on biotech and pharmaceuticals, his thoughts on HHS Secretary RFK Jr., ...

Regeneron CEO Dr. Leonard Schleifer added, "In 2025, we will continue to focus on our four blockbuster medicines as we progress our approximately 40 investigational candidates covering dozens of ...

Trump has hailed the Regeneron therapy as a cure for the virus, but the company’s CEO Leonard Schleifer was quick to point out that the scientific evidence is not there to support the claim.

CEO Leonard Schleifer highlighted 10% revenue growth ... expressed increased concerns about competitive pressures on EYLEA.

Regeneron Pharmaceuticals (NASDAQ ... and relentlessly pursuing cutting-edge science," CEO Leonard Schleifer said. However, Eylea marketed with Bayer (OTCPK:BAYZF) brought $2.3B in net sales ...

Looking back on immuno-oncology stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Regeneron ...

the acquisition of Checkmate will add a promising new modality to Regeneron's toolkit of potential approaches for difficult-to-treat cancers," said Leonard Schleifer, Regeneron's chief executive ...

Regeneron Pharmaceuticals Inc.’s stock ... On a call with analysts, Chief Executive and co-Founder Leonard Schleifer said the U.S. Food and Drug Administration has requested more data from ...